
|Articles|December 11, 2003
LHRH litigation will go forward, court rules
A U.S. District Judge has sustained plaintiff's complaint against the manufacturers of the LHRH agonist leuprolide acetate (Lupron), for improper pricing activities.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










